A Phase 2, double-blind, placebo-controlled trial of sodium selenate as a disease modifying treatment for chronic drug resistant temporal lobe epilepsy (SELECT Trial)

  • O'Brien, Terence (Primary Chief Investigator (PCI))
  • Vivash, Lucy (Chief Investigator (CI))
  • Churilov, Leonid (Chief Investigator (CI))
  • Kwan, Patrick (Chief Investigator (CI))
  • Carney, Patrick (Chief Investigator (CI))
  • Perucca, Piero (Chief Investigator (CI))
  • Nicolo, John-Paul (Chief Investigator (CI))
  • Cook, Mark James (Chief Investigator (CI))
  • Gillinder, Lisa (Chief Investigator (CI))
  • Casillas-Espinosa, Pablo (Chief Investigator (CI))
  • Hovens, Chris M. (Chief Investigator (CI))
  • Malpas, Charles (Chief Investigator (CI))
  • Shultz, Sandy (Chief Investigator (CI))
  • Velakoulis, Dennis (Chief Investigator (CI))
  • Lawn, Nicholas D. (Chief Investigator (CI))
  • Johns, Hannah (Associate Investigator (AI))
  • Wijayath, Manori (Associate Investigator (AI))
  • Burford, Jane (Associate Investigator (AI))
  • Wait, Lisa (Associate Investigator (AI))
  • D'Souza, Wendyl Jude (Associate Investigator (AI))
  • Reutens, David Charles (Associate Investigator (AI))

Project: Research

Project Details

StatusActive
Effective start/end date1/02/23 → 31/01/28

Keywords

  • Epilepsy
  • Clinical trial
  • antiepileptic drugs